HDR Monotherapy in Prostate Cancer: Radiobiological Considerations When Determining Biologically Effective Dose in Clinical Trials
Tien C, Carlson D, Nath R, Chen Z. HDR Monotherapy in Prostate Cancer: Radiobiological Considerations When Determining Biologically Effective Dose in Clinical Trials. Brachytherapy 2017, 16: s31. DOI: 10.1016/j.brachy.2017.04.038.Peer-Reviewed Original ResearchBiologically Effective DoseHDR monotherapyClinical trialsProstate cancerEffective doseRadiobiological considerationsMonotherapyCancerDoseTrials